SAN FRANCISCO, July 31, 2022 /PRNewswire/ — Dr. Guru Sonpavde is the director of bladder cancer at the Dana-Farber Cancer Institute, an associate professor of medicine at Harvard Medical School, and a practicing physician. dr. Sonpavde, along with the other members of Vial’s Oncology CRO Scientific Advisory Board, will work hand in hand with the Vial team to launch and optimize the new CRO.
Upon joining the board of directors, Dr. Sonpavde: “The primary focus of my career has been developing new drugs and combinations for urinary bladder cancer and prostate and kidney cancer through clinical trials. With new treatments such as immunotherapies, conjugated antibodies and targeted therapies, the field is accelerating towards improved cure rates “However, the clinical trial industry needs to accelerate at the same pace, which is why I look forward to working with Vial to ensure that oncology studies are conducted with the utmost efficiency.”
bottle has worked closely with oncology sponsors and researchers to develop a deep understanding of the nuances of clinical trials and the current pain points in conducting them. The result of that research is a technology-enabled CRO offering that is “Built for Sponsors.” The new Oncology CRO will leverage Vial’s streamlined trial management system that integrates eSource, ePro, EDC and CTMS into a seamless operating system. The CRO also provides additional best-in-class services to sponsors, including more efficient trial start-up processes, a centralized call center for pre-screening, and an unparalleled approach to patient recruitment.
dr. Sonpavde joins Dr. Arati Raodr. Antoni Ribasand dr. Neeraj Agarwal on the Oncology CRO Scientific Advisory Board of Vial. dr. Sonpavde is a leading urological oncologist specializing in bladder cancer. He also led translational projects and developed prognostic classifications and endpoints targeting bladder cancer. In addition to his positions at the Dana-Farber Cancer Institute and Harvard Medical Schooldr. Sonpavde serves on the Genitourinary Committee of the Southwest Oncology Group (SWOG) and the Bladder Cancer Task Force of the Genitourinary Steering Committee of the National Cancer Institute.
View the full release here.
About Vial: Vial’s mission is to enable scientists to cure all human diseases. Vial has delivered on that vision by launching a next-generation Contract Research Organization (CRO) (with launches planned in Ophthalmology CRO, Oncology CRO, Gastroenterology CROand a Neurology CRO), a site network (Dermatology Clinical Trials, Ophthalmic Clinical Trials, Gastroenterology Clinical Studies, Women’s Health Clinical Trials, Neurological Clinical Studies), and technology platform (VialConnect CTMS) to speed up the investigation. Vial has more than 125 employees and is located in San Francisco, Californiaand contributed to more than 750 studies from Phase I to Phase IV.
View original content to download multimedia: https://www.prnewswire.com/news-releases/vial-adds-dr-guru-sonpavde-of-the-dana-farber-cancer-institute-to-their-oncology- cro advisory board-301596538.html